Ferlatum Fol oral solution vial15ml N10
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Iron protein succinylate
Release form
Solution
Composition
15 ml (1 vial) contains: Active ingredient: iron protein suktsinilat 800 mg Excipients: sorbitol, propylene glycol, sodium methyl parahydroxybenzoate, sodium propyl parahydroxybenzoate, flavoring cherry (flavoring Wild black cherry concentrate, vanillin, amyl acetate, minor amounts of other ethers, benzaldehyde, clove buds oil, propylene glycol, diethylene glycol monoethyl ether, water), sodium saccharinate, purified water.
Pharmacological effect
Antianemic drug. Contains iron and calcium folinate. It compensates for the lack of iron and folate in the body. The main function of iron is the transfer of oxygen to the tissues. Iron is part of hemoglobin, myoglobin, iron-containing cytochrome enzymes, transfers electrons and acts as a catalyst for oxidation, hydroxylation and other metabolic processes. Ferlatum Fol contains iron-protein succinate, which is a complex compound where ferric iron atoms are surrounded by semi-synthetic protein carrier preventing damage to the gastric mucosa. The protein carrier dissolves in the duodenum, releasing iron at the site of optimal absorption. From the intestine, ferric iron enters the blood through active absorption, which explains the impossibility of overdose and poisoning. Calcium folinate is the calcium salt of folinic acid, which compensates for the lack of folate in the body.
Pharmacokinetics
Data on the pharmacokinetics of the drug is not provided.
Indications
- treatment of latent and clinically pronounced iron deficiency (iron deficiency anemia) and folates; - prevention of iron deficiency and folate during pregnancy, lactation, active growth, after prolonged bleeding, against the background of inadequate and unbalanced nutrition.
Contraindications
- hemochromatosis; - impaired utilization of iron (including lead anemia, sideroachrestic anemia); - non-deficient anemia (including hemolytic anemia, megaloblastic anemia caused by vitamin B12 deficiency); - chronic pancreatitis; - cirrhosis of the liver; - hypersensitivity to the drug.
Precautionary measures
The drug should be used with caution in gastric ulcer and duodenal ulcer, impaired absorption in the pathology of the small intestine (including enteritis, syndrome of insufficiency of absorption, resection of the small intestine, gastric resection of Billroth II with the inclusion of the duodenum).
Use during pregnancy and lactation
The use of the drug Ferlatum Fol is especially recommended for the prevention and treatment of iron deficiency and folate, which develops during pregnancy and during breastfeeding.
Dosage and administration
Ferlatum Fol should be taken orally before or after a meal. An adult should take 1-2 vials per day in 2 divided doses (in an amount equivalent to 40-80 mg of ferric iron and 0.235-0.470 mg of calcium folinate pentahydrate) or as recommended by a physician. (from the neonatal period) to 1.5 ml / kg / day (in an amount equivalent to 4 mg / kg / day of ferric iron and 0.0235 mg / kg / day of calcium folinate) in 2 divided doses or in accordance with the doctor’s recommendations.1 bottle (15 ml ) contains: iron protein succinylate - 800 mg (equivalent to 40 mg of ferric iron) and 0.235 mg ka Lition of folinate pentahydrate (equivalent to 0.185 mg of folinic acid). Pregnant women for the prevention of iron deficiency anemia - 1 bottle / day. For the treatment of latent or clinically pronounced iron deficiency - 1-2 vials / day in 2 doses. After achieving normal levels of serum iron and hemoglobin, the treatment is continued in a maintenance dose for at least 8-12 weeks. press with a force on the perforator of the lid dispenser so that the powder is poured into the solution in the bottle. Then you should vigorously shake up the contents of the vial, remove the dosing cap and drink the solution from the vial.
Side effects
Rarely: the appearance of gastrointestinal disorders that disappear with dose reduction or drug withdrawal.
Overdose
To date, no signs of intoxication and excessive intake of Ferlatum Fol have been described in the body.
Interaction with other drugs
With simultaneous use was not observed interaction of the drug Ferlatum Fol with other drugs. The absorption of iron can be increased while applyingFerlatum Foul with ascorbic acid in a dose of> 200 mg. Iron absorbability can be reduced with simultaneous use of Ferlatum Fol with antacids. Chloramphenicol causes a delayed response to iron therapy. .Some anticancer and anti-leukemic drugs (including aminopterin, methotrexate and other pterin derivatives) show antagonistic properties in folate.
special instructions
The continuous period of use of the drug Ferlatum Fol should not exceed 6 months, except in cases of chronic blood loss (including menorrhagia, hemorrhoids) and pregnancy. Due to the possible development of allergic reactions, the drug should be carefully prescribed to patients with milk protein intolerance. Ferlatum Fol contains sorbitol therefore, the drug should not be used in patients with hereditary fructose intolerance. The effect on the ability to drive vehicles and control mechanisms The drug does not affect classes of potentially hazardous activities that require increased concentration of attention and quickness of psychomotor reactions (including driving vehicles).